Mizuho Securities Remains a Buy on Axsome Therapeutics (AXSM)

Mizuho Securities analyst Graig Suvannavejh maintained a Buy rating on Axsome Therapeutics (AXSMResearch Report) today and set a price target of $76.00. The company’s shares closed yesterday at $60.79.

According to TipRanks, Suvannavejh is an analyst with an average return of -1.0% and a 44.76% success rate. Suvannavejh covers the Healthcare sector, focusing on stocks such as Harmony Biosciences Holdings, Athira Pharma, and Cerevel Therapeutics Holdings.

Axsome Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $87.44, representing a 43.84% upside. In a report released on September 1, H.C. Wainwright also reiterated a Buy rating on the stock with a $210.00 price target.

See today’s best-performing stocks on TipRanks >>

AXSM market cap is currently $2.45B and has a P/E ratio of -15.51.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Axsome Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing novel therapies for the management of central nervous system disorders. Its product candidates include AXS-02 and AXS-06 which are developing for multiple indications. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Read More on AXSM:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More